London, 26 July 2010 – The MDS UK Patient Support Group has welcomed the decision announced today by the National Institute for Health and Clinical Excellence (NICE) that it will […]

The MDS UK Patient Support Group has announced that it has lodged an appeal against the negative recommendation issued earlier this month by the National Institute for Health and Clinical Excellence (NICE) for the use of Vidaza (azacitidine) in patients with higher-risk myelodysplastic syndrome (MDS).

Only 200 patients helped by £50m fund for extra cancer drugs

Latest update on how the Interim Cancer Drug Fund will be implemented at your local Strategic Health Authority level.

The next Government has the power to invest in the future of cancer care. We need every parliamentary candidate to make a firm commitment to cancer support, and you can make this happen.

Read NICE’s press release, as well as a further article in PharmaTimes

NICE states that azacitidine is not recommended as a treatment option for people with intermediate-2 or high risk myelodysplastic syndromes (MDS)

Prime minister’s office responds to the AML (Acute Myeloid Leukaemia) petition for azacitidine

NICE to lose powers to decide on new drugs.